股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 致：香港交易及結算所有限公司 公司名稱: 美麗田園醫療健康產業有限公司 截至月份: 2026年1月31日 狀態: 新提交 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02373 | 說明 | 普通股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | | 0.000005 | USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | | | USD | | | | 本月底結存 | | | 10,000,000,000 | USD | | 0.000005 | USD | | 50,000 ...

Core Viewpoint - The company forecasts a significant increase in adjusted net profit for 2025, driven by a dual strategy of organic growth and external acquisitions, leading to improved profitability and operational efficiency [1][2]. Group 1: Financial Performance Forecast - The company expects 2025 revenue to be no less than 3 billion yuan, representing a year-on-year growth of at least 16% [1]. - Adjusted net profit is projected to be no less than 380 million yuan, with a year-on-year increase of at least 40%, while net profit is expected to be no less than 340 million yuan, reflecting a growth of at least 34% [1]. - The performance forecast aligns with expectations due to the company's effective dual strategy and operational improvements [1]. Group 2: Growth Drivers - The company anticipates robust organic growth and contributions from acquisitions, with revenue growth expected to be driven by double-digit growth in beauty and health services, and high growth in sub-health medical services [1][2]. - The integration of the acquired company, Nai Rui Er, is expected to enhance operational efficiency and contribute to revenue growth in 2025 [1][2]. - The company reported strong performance during the year-end "Double Festival" period, with revenue from its main business segments showing positive year-on-year growth [1]. Group 3: Profitability Enhancement - The company forecasts an adjusted net profit margin of 12.7% for 2025, an increase of 2 percentage points year-on-year, driven by a higher proportion of high-margin medical services and operational efficiency improvements [2]. - The integration of Nai Rui Er is expected to further enhance profitability through effective resource integration and operational empowerment [2]. Group 4: Strategic Outlook - The company completed the acquisition of Si Yan Li on January 7, 2026, which will contribute to revenue growth and operational efficiency, leveraging the integration experience from Nai Rui Er [2]. - The company is optimistic about its growth potential under the "super brand, super chain, super digitalization" strategy, which is expected to enhance market bargaining power [2]. Group 5: Earnings Forecast and Valuation - The company maintains its profit forecast for 2025 and has increased the 2026 net profit estimate by 20% to 430 million yuan, with projections for 2027 at 540 million yuan [2]. - The current stock price corresponds to a price-to-earnings ratio of 13x for 2026 and 10x for 2027, with a target price of 42 HKD, indicating a potential upside of 57% [2].

美丽田园医疗健康(02373)公布，2026年1月28日耗资约125.63万港元回购4.65万股股份。 ...

智通财经APP讯，美丽田园医疗健康(02373)公布，2026年1月28日耗资约125.63万港元回购4.65万股股 份。 ...

FF305 呈交日期： 2026年1月28日 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 美麗田園醫療健康產業有限公司 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02373 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | | 佔有關事件前的現有已發 | | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a potential upside of over 15% relative to the benchmark index [3][13]. Core Insights - The company is expected to achieve a revenue of at least 3 billion RMB in 2025, representing a year-on-year growth of no less than 16%. Adjusted net profit is projected to be at least 380 million RMB, with a year-on-year increase of no less than 40% [9]. - The company's performance is driven by both organic growth and external expansion, with significant contributions from the acquisition of the second-ranked beauty brand, Nair, enhancing market share and profitability [9]. - The successful acquisition of Shanghai Siyuanli, a well-known brand in the high-end beauty service sector, is expected to further strengthen the company's market position and resource density [9]. - The integration of the top three brands in the industry is anticipated to continuously release the company's leading effect, promoting a "super brand, super chain, and super digitalization" strategy to reshape the beauty industry's value space [9]. Financial Projections - Revenue forecasts for 2025-2027 are 30.20 billion RMB, 39.86 billion RMB, and 45.84 billion RMB, with growth rates of 17.4%, 32.0%, and 15.0% respectively [3][11]. - Adjusted net profit is projected to be 3.85 billion RMB in 2025, 5.10 billion RMB in 2026, and 6.00 billion RMB in 2027, with year-on-year growth rates of 52.8%, 32.4%, and 17.6% respectively [3][11]. - The earnings per share (EPS) based on adjusted net profit is expected to be 1.53 RMB in 2025, 2.03 RMB in 2026, and 2.38 RMB in 2027, with corresponding price-to-earnings (P/E) ratios of 17, 13, and 11 [3][11].

智通财经APP获悉，开源证券发布研报称，考虑美丽田园医疗健康(02373)坚定"内生+外延"双轮驱动战 略，清晰的战略路径有望重塑美业价值新空间，该行上调盈利预测，预计公司2025-2027年归母净利润 为3.42/4.36/4.91亿元（原值为3.10/4.06/4.72亿元），对应EPS为1.36/1.73/1.95元，当前股价对应PE为 18.0/14.1/12.5倍，维持"买入"评级。 开源证券主要观点如下： 公司发布正面盈利预告，预计2025年净利润同比增长不低于34% 公司发布业绩预告：2025年预计实现收入不少于30亿元（同比+16%及以上），经调净利润不低于3.8亿 元（同比+40%及以上）；净利润不低于3.4亿元（同比+34%及以上），业绩增长强劲，展现出穿越经 济周期的强大韧性和发展潜力。 打通"内生+外延"发展路径，高整合能力驱动规模扩张 （1）外延扩张加速：公司收购贝黎诗、奈瑞儿等优质品牌并实现成功整合，逐步完善"双美+双保健"业 务版图。其中，2025H1奈瑞儿经调净利率从收购前6.5%大幅跃升至10.4%，充分印证公司的资源整合与 运营赋能能力。此外，2025年10月15日，美丽田 ...

公司发布正面盈利预告，预计2025 年净利润同比增长不低于34% 通过连锁克服行业高度分散格局，公司将从"1 到N"在中国20 个核心城市打造"1 亿元收入Club"并强化 供应链自主可控能力；（3）超级数字化：美丽田园的精准推送活动以低于2%的获客费用撬动高达80% 的新会员次年留存率，公司将持续推动数智融合发展，将AI 能力融入产品创新。 风险提示：门店整合效果不及预期，门店拓展不及预期，医疗事故风险。 公司发布业绩预告：2025 年预计实现收入不少于30 亿元（同比+16%及以上），经调净利润不低于3.8 亿元（同比+40%及以上）；净利润不低于3.4 亿元（同比+34%及以上），业绩增长强劲，展现出穿越 经济周期的强大韧性和发展潜力。考虑公司坚定"内生+外延"双轮驱动战略，清晰的战略路径有望重塑 美业价值新空间，我们上调盈利预测，预计公司2025-2027 年归母净利润为3.42/4.36/4.91亿元（原值为 3.10/4.06/4.72 亿元），对应EPS 为1.36/1.73/1.95 元，当前股价对应PE 为18.0/14.1/12.5 倍，维持"买 入"评级。 机构：开源证券 （1）外延扩张 ...

Group 1: Industry Insights - The silicon photonics industry is experiencing clear trends, with accelerated development in CPO (Co-Packaged Optics) technology. NVIDIA's recent announcements at CES 2026 highlight advancements in supercomputing and optical devices, indicating a growing demand for CPO and related technologies [6][11][12] - The Vera Rubin cabinet features significant technological advancements, including 20 trillion transistors and enhanced memory capacities, which are expected to drive demand for CPO, optical modules, and liquid cooling solutions [6][11][12] - The CPO industry is evolving rapidly, with potential growth in demand for silicon photonics components, including optical engines and related manufacturing processes. Key sectors benefiting from this trend include optical interconnects and passive components [13][14] Group 2: Company Updates - Ji Hong Co., Ltd. (吉宏股份) - Ji Hong Co., Ltd. forecasts a 50%-60% year-on-year increase in net profit for 2025, with expected net profit ranging from 273 to 291 million yuan. The Q4 2025 net profit is projected to be between 57 to 75 million yuan, reflecting strong performance [7][16] - The company's growth is driven by its dual strategy of packaging and cross-border social e-commerce, leveraging AI technology to enhance operational efficiency and expand market reach [17][18] Group 3: Company Updates - Beautiful Pastoral Medical Health (美丽田园医疗健康) - Beautiful Pastoral Medical Health anticipates a net profit growth of no less than 34% for 2025, with expected revenue of at least 3 billion yuan, reflecting a strong resilience and growth potential [8][20] - The company is focusing on a dual growth strategy of internal development and external acquisitions, successfully integrating brands to enhance its market position and operational capabilities [21][22] Group 4: Company Updates - Poly Developments (保利发展) - Poly Developments expects a slight decline in revenue for 2025, with net profit significantly impacted by impairment provisions. However, the company maintains a leading sales position and continues to optimize its land reserve structure [9][25][26] - The company projects a net profit of 1.03 billion yuan for 2025, down 79.5% year-on-year, primarily due to increased impairment losses. Despite this, the company remains optimistic about future performance as low-cost project completions are expected to drive recovery [25][26][27]

2025年10月15日，港股"美容院第一股"美丽田园医疗健康（02373.HK）宣布以12.5亿元人民币的对价， 全资收购上海思妍丽实业股份有限公司。这不仅是2025年中国美业规模最大的一笔收购案，更标志着一 个新时代的到来：行业前三的品牌——美丽田园、奈瑞儿、思妍丽——首次齐聚于同一资本麾下。 交易采用"现金+股份"的支付方式，其中现金支付约8.36亿元，并向思妍丽原控股股东SYL Holding配发 约1579.8万股对价股份，使其成为美丽田园持股约6.28%的股东。 战略图谱：为何是思妍丽？解码12.5亿收购案的核心逻辑 交易达成只是第一步，真正的考验在于整合。市场用股价泼了一盆冷水：收购公告当日，美丽田园股价 高开低走，最终收跌5.43%。这折射出资本市场对巨无霸合并后协同效应能否实现的深层疑虑。 首当其冲的挑战是"品牌协同与内部竞争"。美丽田园旗下已拥有美丽田园、贝黎诗、奈瑞儿等多个定位 高端的品牌，如今再加入思妍丽，难免令人担忧品牌间会左右互搏、争夺客源。 此次收购并非一次冲动之举，而是美丽田园基于清晰的行业判断和自身发展战略，进行的一次精密布 局。其背后，是公司对高端美容市场"赢家通吃"未来的坚 ...